Health Canada has granted marketing authorisation for Bayer’s oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).   This authorisation is based on results from the Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression or death by 46% compared […]